You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Details for Patent: 10,028,925


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,028,925
Title:Liquid dosage forms of sodium naproxen
Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
Inventor(s): Chidambaram; Nachiappan (Sandy, UT), Fatmi; Aqeel A (High Point, NC)
Assignee: Patheon Softgels, Inc. (High Point, NC)
Application Number:15/591,512
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,028,925
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,028,925

Introduction

United States Patent 10,028,925 is part of a broader patent landscape that involves complex legal and technical aspects. This patent, along with others in its family, is often involved in infringement disputes and litigation. Here, we will delve into the details of this patent, its claims, and the surrounding patent landscape.

Patent Overview

The United States Patent 10,028,925 is one of the patents asserted in a civil action for infringement, as detailed in the complaint filed by PSI and Bionpharma against PuraCap[2].

Patent Claims

The patent in question, 10,028,925, is part of a group of patents that include:

  • 9,693,978 (the '978 patent)
  • 9,693,979 (the '979 patent)
  • 10,022,344 (the '344 patent)
  • 10,028,925 (the '925 patent)

These patents are collectively referred to as the "Asserted Patents" in the litigation. The claims of these patents are crucial in determining the scope of protection and potential infringement.

Claim Analysis

To understand the scope of the patent, it is essential to analyze the claims. Here are some key points:

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. The length and count of independent claims can provide insights into the patent's scope and complexity[3].

Claim Language

The language used in the claims is critical. Broader claims may encompass a wider range of inventions but are more likely to face challenges regarding validity and enforceability. Narrower claims, on the other hand, may be more specific but could limit the scope of protection[3].

Patent Scope

The scope of a patent is a vital aspect in determining its validity and enforceability. Here are some metrics and considerations:

Independent Claim Length and Count

Research suggests that narrower claims, as measured by independent claim length and count, are associated with a higher probability of grant and a shorter examination process. This indicates that the patent office tends to narrow the scope of patent claims during the examination process[3].

Forward Citations and Patent Maintenance Payments

Forward citations (citations by later patents) and patent maintenance payments can also indicate the scope and importance of a patent. Patents with more forward citations and higher maintenance payments are generally considered more valuable and broader in scope[3].

Litigation Context

The patent 10,028,925 is part of ongoing litigation involving PSI, Bionpharma, and PuraCap. Here are some key points from the litigation:

Parties Involved

  • Plaintiffs: PSI and Bionpharma, both Delaware corporations.
  • Defendant: PuraCap, a New Jersey corporation.

Nature of the Action

The action is based on the infringement of the Asserted Patents, including the '925 patent. The complaint alleges that PuraCap's actions constitute infringement of these patents under the Patent Laws of the United States[2].

Patent Landscape

The patent landscape surrounding 10,028,925 involves several key aspects:

Patent Family

The '925 patent is part of a family of patents that include related inventions. This family can provide a broader understanding of the technological area and the scope of protection.

Industry Context

Patents in the pharmaceutical and biotechnology sectors, like those involved in this litigation, often face intense scrutiny and litigation. The validity and enforceability of these patents are frequently challenged, and settlements or judgments can have significant financial implications[5].

Examples and Statistics

In the context of pharmaceutical patents, the scope and claims can significantly impact the market. For instance:

Settlements and Judgments

In cases like Celgene Corp. v. Hikma Pharms. USA, Inc. and Vanda Pharms. Inc. v. MSN Pharms. Inc., the scope of the patents and the claims played a crucial role in determining the outcome of the litigation. These cases often result in significant settlements or judgments, highlighting the importance of patent scope and claims[5].

Expert Insights

Industry experts often emphasize the importance of clear and narrow claims to avoid litigation and ensure the validity of patents.

"Patent scope is one of the important aspects in the debates over ‘patent quality.’ The purported decrease in patent quality over the past decade or two has supposedly led to granting patents of increased breadth (or ‘overly broad’ patents), decreased clarity, and questionable validity."[3]

Key Takeaways

  • Patent Claims: The claims of the '925 patent, along with other Asserted Patents, are critical in determining the scope of protection and potential infringement.
  • Patent Scope: Metrics such as independent claim length and count, forward citations, and patent maintenance payments can indicate the scope and importance of a patent.
  • Litigation Context: The patent is part of ongoing litigation involving PSI, Bionpharma, and PuraCap, highlighting the importance of clear and enforceable claims.
  • Industry Context: Patents in the pharmaceutical sector face intense scrutiny, and the scope and claims can significantly impact market outcomes.

FAQs

  1. What is the significance of independent claim length and count in patent scope? Independent claim length and count are metrics that indicate the complexity and breadth of a patent. Narrower claims are associated with a higher probability of grant and a shorter examination process[3].

  2. How does the patent landscape affect the validity and enforceability of patents like 10,028,925? The patent landscape, including the family of related patents and industry context, can significantly impact the validity and enforceability of patents. Broader patents may face more challenges, while narrower patents may be more specific but less broad in scope[3].

  3. What are the implications of patent scope in pharmaceutical litigation? In pharmaceutical litigation, the scope of patents can have significant financial implications. Clear and narrow claims can help avoid litigation and ensure the validity of patents, while broader claims may lead to increased licensing and litigation costs[3].

  4. How do forward citations and patent maintenance payments relate to patent scope? Forward citations and higher patent maintenance payments generally indicate a broader and more valuable patent scope. These metrics suggest that the patent is more important and widely recognized in the field[3].

  5. What role do settlements and judgments play in determining the scope of pharmaceutical patents? Settlements and judgments in pharmaceutical patent litigation often hinge on the scope and claims of the patents involved. These outcomes can set precedents and influence future patent strategies in the industry[5].

Sources

  1. IPWatchdog - Patent Filings Roundup: NPE Targets Cracker Barrel, Realtors ...
  2. Walsh Pizzi O'Reilly Jupiter & Fullam LLP - Liza M. Walsh Katelyn O'Reilly William T. Walsh, Jr.
  3. SSRN - Patent Claims and Patent Scope
  4. Ariat - Lucy Wide Leg Trouser Mid Rise - Ladies Jeans
  5. Robins Kaplan LLP - ANDA Litigation Settlements | Hatch-Waxman

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,028,925

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free Y TEMPORARY RELIEF OF MINOR ACHES AND PAINS ⤷  Try for Free
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free Y TEMPORARY REDUCTION OF FEVER ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,028,925

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2600023 ⤷  Try for Free
China 101166520 ⤷  Try for Free
China 102940887 ⤷  Try for Free
Cyprus 1118321 ⤷  Try for Free
Denmark 1863458 ⤷  Try for Free
European Patent Office 1863458 ⤷  Try for Free
European Patent Office 3061447 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.